Business Context and Reporting Period
Apyx Medical Corporation (APYX) filed a Form 8-K on May 7, 2026, to report its results of operations for the first quarter ended March 31, 2026. The company is incorporated in Delaware and its Class A common stock trades on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the earnings press release attached as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. It serves solely as a notification that the Q1 2026 results have been issued.
Guidance, Outlook, and Risks
This 8-K does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. Such information is expected to be found in the referenced press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings press release) for actual Q1 2026 financial figures.
- Verify year-over-year revenue and net income trends in the full press release.
- Check for any updated full-year 2026 guidance provided in the press release.
- Confirm cash position and liquidity status as detailed in the attached exhibit.